The Patent Finder

Merck & Cie

Also on record
Records under this name other than the patents Merck & Cie holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 18 patents it holds.

Back to Merck & Cie

PatentTitleStatus Expires Confidence
US 11,066,408Crystalline Binary Sodium Salts of 5-Methyl-(6S)-TETRAHYDROFOLIC Acid with Organic Bases
now held by Merck Patent GmbH
In force
 · High confidence
In forceHigh confidence
US 7,727,987Crystalline Forms of ( 6R)-L-ERYTHRO-TETRAHYDROBIOPTERIN Dihydrochloride
Term ended
Term ended Oct 14, 2025 · High confidence
Term endedTerm ended Oct 14, 2025High confidence
US 9,771,36818F-LABELLED Folates
Lapsed on the fee record
Ended Sep 26, 2025 · High confidence
Lapsed on the fee recordEnded Sep 26, 2025High confidence
US 8,318,745Crystalline Forms of (6R)-L-ERYTHRO-TETRAHYDROBIOPTERIN Dihydrochloride
Term ended
Term ended Nov 17, 2024 · High confidence
Term endedTerm ended Nov 17, 2024High confidence
US 8,344,139Process for Preparing Crystalline Polymorphic Forms of (6R)-L-ERYTHRO-TETRAHYDROBIOPTERIN Dihydrochloride
Term ended
Term ended Nov 17, 2024 · High confidence
Term endedTerm ended Nov 17, 2024High confidence
US 6,858,731Process for the Preparation of Pure Stereoisomers of Tetrahydrofolic Acid Ester Salts and Tetrahydrofolic Acid by Fractionated Crystallisation of Tetrahydrofolic Acid Ester Salts
Term ended
Term ended Jul 19, 2020 · High confidence
Term endedTerm ended Jul 19, 2020High confidence
US 7,816,525Process for the Preparation of Optically Pure Tetrahydropterins and Derivatives, and Specifically of Optically Pure Tetrahydrofolic Acid and Derivatives Thereof, by Stereospecific Hydrogenation
Term ended
Term ended Jul 12, 2020 · High confidence
Term endedTerm ended Jul 12, 2020High confidence
US 6,995,158Pharmaceutical Preparation Containing at Least Folic Acid or a Folate and Tetrahydrobiopterin (BH4) or Derivatives Thereof Used for the Treating or Preventing Cardiovascular or Neurological Disorders by Modulation of the Activity of Nitric Oxide Synthase (NOS)
Term ended
Ended no later than Jun 7, 2020 · Low confidence
Term endedEnded no later than Jun 7, 2020Low confidence
11/435,198Pharmaceutical composition comprising progestogens and/or estrogens and 5-methyl- (6S)-tetrahydrofolate
Abandoned
Abandoned May 20, 2013
AbandonedAbandoned May 20, 2013
11/938,688Pharmaceutical Composition Comprising Progestogens And/Or Estrogens and 5-Methyl-(6S)-TETRAHYDROFOLATE
Abandoned
Abandoned Mar 17, 2016
AbandonedAbandoned Mar 17, 2016
10 of 22 records shown.
Pro members see all 22.
Pro members: see all 22 records
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited